Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 175

1.

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.

Mease PJ, Smolen JS, Behrens F, Nash P, Liu Leage S, Li L, Tahir H, Gooderham M, Krishnan E, Liu-Seifert H, Emery P, Pillai SG, Helliwell PS; SPIRIT H2H study group.

Ann Rheum Dis. 2020 Jan;79(1):123-131. doi: 10.1136/annrheumdis-2019-215386. Epub 2019 Sep 28.

2.

Water Vapor Adsorption-Desorption Behavior of Surfactant-Coated Starch Particles for Commercial Energy Wheels.

Shakouri M, Krishnan EN, Karoyo AH, Dehabadi L, Wilson LD, Simonson CJ.

ACS Omega. 2019 Aug 28;4(11):14378-14389. doi: 10.1021/acsomega.9b00755. eCollection 2019 Sep 10.

3.

Effectiveness of point-of-use/point-of-entry systems to remove per- and polyfluoroalkyl substances from drinking water.

Patterson C, Burkhardt J, Schupp D, Krishnan ER, Dyment S, Merritt S, Zintek L, Kleinmaier D.

AWWA Water Sci. 2019;1(2):1-12. doi: 10.1002/aws2.1131.

4.

An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis.

Cohen S, Pablos JL, Pavelka K, Müller GA, Matsumoto A, Kivitz A, Wang H, Krishnan E.

Arthritis Res Ther. 2019 Mar 29;21(1):84. doi: 10.1186/s13075-019-1857-3.

5.

Evaluation of an environmentally sustainable UV-assisted water treatment system for the removal of Bacillus globigii spores in water.

Silva RG, Szabo J, Namboodiri V, Krishnan ER, Rodriguez J, Zeigler A.

Water Sci Technol Water Supply. 2018 Jun;18(3):968-975. doi: 10.2166/ws.2017.165.

6.

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.

van der Heijde D, Cheng-Chung Wei J, Dougados M, Mease P, Deodhar A, Maksymowych WP, Van den Bosch F, Sieper J, Tomita T, Landewé R, Zhao F, Krishnan E, Adams DH, Pangallo B, Carlier H; COAST-V study group.

Lancet. 2018 Dec 8;392(10163):2441-2451. doi: 10.1016/S0140-6736(18)31946-9. Epub 2018 Oct 22.

PMID:
30360964
7.

Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors.

Deodhar A, Poddubnyy D, Pacheco-Tena C, Salvarani C, Lespessailles E, Rahman P, Järvinen P, Sanchez-Burson J, Gaffney K, Lee EB, Krishnan E, Santisteban S, Li X, Zhao F, Carlier H, Reveille JD; COAST-W Study Group.

Arthritis Rheumatol. 2019 Apr;71(4):599-611. doi: 10.1002/art.40753. Epub 2019 Mar 8.

8.

A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement.

Fountzilas E, Krishnan E, Janku F, Fu S, Karp DD, Naing A, Subbiah V, Hong DS, Piha-Paul SA, Vining DJ, Tsimberidou AM.

Cancer Chemother Pharmacol. 2018 Nov;82(5):877-885. doi: 10.1007/s00280-018-3680-y. Epub 2018 Sep 4.

PMID:
30182147
9.

Mast Cell-Dependent CD8+ T-cell Recruitment Mediates Immune Surveillance of Intestinal Tumors in ApcMin/+ Mice.

Bodduluri SR, Mathis S, Maturu P, Krishnan E, Satpathy SR, Chilton PM, Mitchell TC, Lira S, Locati M, Mantovani A, Jala VR, Haribabu B.

Cancer Immunol Res. 2018 Mar;6(3):332-347. doi: 10.1158/2326-6066.CIR-17-0424. Epub 2018 Jan 30.

10.

Leukotriene B4-receptor-1 mediated host response shapes gut microbiota and controls colon tumor progression.

Jala VR, Maturu P, Bodduluri SR, Krishnan E, Mathis S, Subbarao K, Wang M, Jenson AB, Proctor ML, Rouchka EC, Knight R, Haribabu B.

Oncoimmunology. 2017 Aug 10;6(12):e1361593. doi: 10.1080/2162402X.2017.1361593. eCollection 2017.

11.

Inactivation of Bacillus Spores in Wash Waters Using Dilute Chlorine Bleach Solutions at Different Temperatures and pH Levels.

Gallardo VJ, Schupp DA, Heckman JL, Krishnan ER, Rice EW.

Water Environ Res. 2018 Feb 1;90(2):110-121. doi: 10.2175/106143017X14902968254719. Epub 2017 Jun 23.

12.

Initial Poor Function and Primary Nonfunction in Deceased-Donor Orthotopic Liver Transplantation Maintaining Short Cold Ischemic Time.

Das S, Swain SK, Addala PK, Balasubramaniam R, Gopakumar CV, Zirpe D, Renganathan K, Kollu H, Patel D, Vibhute BB, Rao PS, Krishnan E, Gopasetty M, Khakhar AK, Vaidya A, Ramamurthy A.

Prog Transplant. 2016 Dec;26(4):340-347. doi: 10.1177/1526924816663516. Epub 2016 Aug 20.

PMID:
27543202
13.

Validity and measurement precision of the PROMIS physical function item bank and a content validity-driven 20-item short form in rheumatoid arthritis compared with traditional measures.

Oude Voshaar MA, Ten Klooster PM, Glas CA, Vonkeman HE, Taal E, Krishnan E, Bernelot Moens HJ, Boers M, Terwee CB, van Riel PL, van de Laar MA.

Rheumatology (Oxford). 2015 Dec;54(12):2221-9. doi: 10.1093/rheumatology/kev265. Epub 2015 Jul 29.

PMID:
26224306
14.

Large-Scale and Comprehensive Immune Profiling and Functional Analysis of Normal Human Aging.

Whiting CC, Siebert J, Newman AM, Du HW, Alizadeh AA, Goronzy J, Weyand CM, Krishnan E, Fathman CG, Maecker HT.

PLoS One. 2015 Jul 21;10(7):e0133627. doi: 10.1371/journal.pone.0133627. eCollection 2015.

15.

Establishing a Common Metric for Physical Function: Linking the HAQ-DI and SF-36 PF Subscale to PROMIS(®) Physical Function.

Schalet BD, Revicki DA, Cook KF, Krishnan E, Fries JF, Cella D.

J Gen Intern Med. 2015 Oct;30(10):1517-23. doi: 10.1007/s11606-015-3360-0.

16.

Crystalline silica-induced leukotriene B4-dependent inflammation promotes lung tumour growth.

Satpathy SR, Jala VR, Bodduluri SR, Krishnan E, Hegde B, Hoyle GW, Fraig M, Luster AD, Haribabu B.

Nat Commun. 2015 Apr 29;6:7064. doi: 10.1038/ncomms8064.

17.
18.

Validation of the ICD-9-CM code for systemic sclerosis using updated ACR/EULAR classification criteria.

Valenzuela A, Yaqub A, Fiorentino D, Krishnan E, Chung L.

Scand J Rheumatol. 2015 May;44(3):253-5. doi: 10.3109/03009742.2015.1008038. Epub 2015 Mar 6. No abstract available.

PMID:
25744697
19.

Big data and clinicians: a review on the state of the science.

Wang W, Krishnan E.

JMIR Med Inform. 2014 Jan 17;2(1):e1. doi: 10.2196/medinform.2913. Review.

20.

Cigarette smoking is associated with a reduction in the risk of incident gout: results from the Framingham Heart Study original cohort.

Wang W, Krishnan E.

Rheumatology (Oxford). 2015 Jan;54(1):91-5. doi: 10.1093/rheumatology/keu304. Epub 2014 Aug 1.

PMID:
25086327
21.

A short tutorial on item response theory in rheumatology.

Siemons L, Krishnan E.

Clin Exp Rheumatol. 2014 Jul-Aug;32(4):581-6. Epub 2014 Jul 23. Review.

PMID:
25065775
22.

Relative performance of commonly used physical function questionnaires in rheumatoid arthritis and a patient-reported outcomes measurement information system computerized adaptive test.

Oude Voshaar MA, Ten Klooster PM, Glas CA, Vonkeman HE, Krishnan E, van de Laar MA.

Arthritis Rheumatol. 2014 Oct;66(10):2900-8. doi: 10.1002/art.38759.

23.

Extending the floor and the ceiling for assessment of physical function.

Fries JF, Lingala B, Siemons L, Glas CA, Cella D, Hussain YN, Bruce B, Krishnan E.

Arthritis Rheumatol. 2014 May;66(5):1378-87. doi: 10.1002/art.38342.

24.

Gout in African Americans.

Krishnan E.

Am J Med. 2014 Sep;127(9):858-64. doi: 10.1016/j.amjmed.2014.03.039. Epub 2014 Apr 24.

PMID:
24768965
25.

Aging, not menopause, is associated with higher prevalence of hyperuricemia among older women.

Krishnan E, Bennett M, Chen L.

Menopause. 2014 Nov;21(11):1211-6. doi: 10.1097/GME.0000000000000230.

PMID:
24714624
26.

Calibration of the PROMIS physical function item bank in Dutch patients with rheumatoid arthritis.

Oude Voshaar MA, ten Klooster PM, Glas CA, Vonkeman HE, Taal E, Krishnan E, Moens HJ, Boers M, Terwee CB, van Riel PL, van de Laar MA.

PLoS One. 2014 Mar 17;9(3):e92367. doi: 10.1371/journal.pone.0092367. eCollection 2014.

27.
28.

Reply: To PMID 23982888.

Krishnan E.

Arthritis Rheumatol. 2014 Jun;66(6):1686. doi: 10.1002/art.38386. No abstract available.

29.

Health and exercise-related medical issues among 1,212 ultramarathon runners: baseline findings from the Ultrarunners Longitudinal TRAcking (ULTRA) Study.

Hoffman MD, Krishnan E.

PLoS One. 2014 Jan 8;9(1):e83867. doi: 10.1371/journal.pone.0083867. eCollection 2014.

30.

Body mass index and its correlates in 1,212 ultramarathon runners: baseline findings from the ULTRA study.

Hoffman MD, Chen L, Krishnan E.

J Phys Act Health. 2014 Nov;11(8):1549-55. doi: 10.1123/jpah.2013-0056. Epub 2013 Dec 31.

PMID:
24385475
31.
32.

Development and assessment of floor and ceiling items for the PROMIS physical function item bank.

Bruce B, Fries J, Lingala B, Hussain YN, Krishnan E.

Arthritis Res Ther. 2013 Oct 3;15(5):R144. doi: 10.1186/ar4327.

33.

Gout and the heart.

Bhole V, Krishnan E.

Rheum Dis Clin North Am. 2014 Feb;40(1):125-43. doi: 10.1016/j.rdc.2013.10.004. Review.

PMID:
24268013
34.
35.

Atherosclerotic cardiovascular disease in hospitalized patients with systemic sclerosis: higher mortality than patients with lupus and rheumatoid arthritis.

Dave AJ, Fiorentino D, Lingala B, Krishnan E, Chung L.

Arthritis Care Res (Hoboken). 2014 Feb;66(2):323-7. doi: 10.1002/acr.22152.

36.

Filipino gout: a review.

Prasad P, Krishnan E.

Arthritis Care Res (Hoboken). 2014 Mar;66(3):337-43. doi: 10.1002/acr.22118. Review. No abstract available.

37.
38.

Exercise behavior of ultramarathon runners: baseline findings from the ULTRA study.

Hoffman MD, Krishnan E.

J Strength Cond Res. 2013 Nov;27(11):2939-45. doi: 10.1519/JSC.0b013e3182a1f261.

PMID:
23838972
39.

The components of action planning and their associations with behavior and health outcomes.

Lorig K, Laurent DD, Plant K, Krishnan E, Ritter PL.

Chronic Illn. 2014 Mar;10(1):50-9. doi: 10.1177/1742395313495572. Epub 2013 Jul 9.

PMID:
23838837
40.

Upper-extremity and mobility subdomains from the Patient-Reported Outcomes Measurement Information System (PROMIS) adult physical functioning item bank.

Hays RD, Spritzer KL, Amtmann D, Lai JS, Dewitt EM, Rothrock N, Dewalt DA, Riley WT, Fries JF, Krishnan E.

Arch Phys Med Rehabil. 2013 Nov;94(11):2291-6. doi: 10.1016/j.apmr.2013.05.014. Epub 2013 Jun 8.

41.

Mediastinal paraganglioma between the great vessels in an 81-year-old woman.

Ghouri MA, Krishnan E, Singh A, Zaman T, Hallman CH.

Tex Heart Inst J. 2013;40(2):189-92.

42.

Serum urate and incidence of kidney disease among veterans with gout.

Krishnan E, Akhras KS, Sharma H, Marynchenko M, Wu E, Tawk RH, Liu J, Shi L.

J Rheumatol. 2013 Jul;40(7):1166-72. doi: 10.3899/jrheum.121061. Epub 2013 May 15.

43.

Relative and attributable diabetes risk associated with hyperuricemia in US veterans with gout.

Krishnan E, Akhras KS, Sharma H, Marynchenko M, Wu EQ, Tawk R, Liu J, Shi L.

QJM. 2013 Aug;106(8):721-9. doi: 10.1093/qjmed/hct093. Epub 2013 Apr 24.

44.

Brief report: citrullination within the atherosclerotic plaque: a potential target for the anti-citrullinated protein antibody response in rheumatoid arthritis.

Sokolove J, Brennan MJ, Sharpe O, Lahey LJ, Kao AH, Krishnan E, Edmundowicz D, Lepus CM, Wasko MC, Robinson WH.

Arthritis Rheum. 2013 Jul;65(7):1719-24. doi: 10.1002/art.37961.

45.

Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout.

Perez-Ruiz F, Martínez-Indart L, Carmona L, Herrero-Beites AM, Pijoan JI, Krishnan E.

Ann Rheum Dis. 2014 Jan;73(1):177-82. doi: 10.1136/annrheumdis-2012-202421. Epub 2013 Jan 12.

PMID:
23313809
46.

Atherosclerotic cardiovascular disease and dermatomyositis: an analysis of the Nationwide Inpatient Sample survey.

Linos E, Fiorentino D, Lingala B, Krishnan E, Chung L.

Arthritis Res Ther. 2013 Jan 8;15(1):R7. doi: 10.1186/ar4135.

47.

Reduced glomerular function and prevalence of gout: NHANES 2009-10.

Krishnan E.

PLoS One. 2012;7(11):e50046. doi: 10.1371/journal.pone.0050046. Epub 2012 Nov 27.

48.

Pegloticase and the patient with treatment-failure gout.

Dave AJ, Kelly VM, Krishnan E.

Expert Rev Clin Pharmacol. 2012 Sep;5(5):501-8. doi: 10.1586/ecp.12.48.

PMID:
23121270
49.

Decline in miR-181a expression with age impairs T cell receptor sensitivity by increasing DUSP6 activity.

Li G, Yu M, Lee WW, Tsang M, Krishnan E, Weyand CM, Goronzy JJ.

Nat Med. 2012 Oct;18(10):1518-24. doi: 10.1038/nm.2963. Epub 2012 Sep 30.

50.

Low-level lead exposure and the prevalence of gout: an observational study.

Krishnan E, Lingala B, Bhalla V.

Ann Intern Med. 2012 Aug 21;157(4):233-41. doi: 10.7326/0003-4819-157-4-201208210-00003.

PMID:
22910934

Supplemental Content

Loading ...
Support Center